Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus amylovorus

What does the research say about Lactobacillus amylovorus?

3 health outcomes synthesised

Research on Lactobacillus amylovorus spans three health outcomes: improved growth performance, reduced inflammation, and improved intestinal barrier function. The strongest evidence pertains to growth performance, with four studies showing beneficial effects, though all were conducted in livestock and aquaculture species—relevance to humans remains unknown. No effective doses were reported in any study, and human data are entirely lacking.

Strongest evidence The most robust evidence is for improved growth performance (moderate evidence strength). All 4 studies reported beneficial effects, with effect sizes ranging from small to large (two moderate, one small, one large). Populations studied include weaning pigs, newborn piglets, lambs, and Asian seabass fingerlings. However, doses were not reported in any study, and the evidence is limited to animal models.

Mixed or weaker evidence For reduced inflammation (low evidence strength), 4 studies all showed beneficial effects, but only one is a human meta-analysis (25 RCTs) reporting a small but statistically significant reduction in C-reactive protein (-0.99 mg/L); the other three are in vitro or animal studies that may not translate to humans. For improved intestinal barrier function (low evidence strength), 3 studies reported moderate beneficial effects, but 2 of them co-administered other interventions (Bacillus subtilis, epigallocatechin), making the specific contribution of L. amylovorus uncertain. No human data exist for this outcome.

Effective dose patterns No effective doses were reported across any of the syntheses. The effectiveDose field is null for all three outcomes, meaning the research literature has not established a consistent dose or form for any health effect.

Population insights All available evidence comes from animal models—primarily piglets, lambs, and fish—with no direct human studies. The most studied populations are weaning and newborn piglets for growth performance. No human subpopulations (e.g., elderly, deficient groups) have been evaluated.

Notable caveats

  • The evidence base is very small (3-4 studies per outcome) and should be considered preliminary.
  • Publication bias is a concern: overwhelmingly positive results may reflect preferential publication of beneficial findings.
  • Two of three intestinal barrier studies involved co-interventions, confounding the specific effect of L. amylovorus.
  • Even the strongest evidence (growth performance) is from livestock and may not translate to humans due to differences in physiology and gut microbiota.
  • No dosing information is available from any study, limiting clinical applicability.

Frequently asked

  • What is Lactobacillus amylovorus good for according to research?
    Current research suggests potential benefits for improved growth performance, reduced inflammation, and improved intestinal barrier function. Evidence is strongest for growth performance (4 animal studies, moderate evidence), but all findings come from livestock or aquaculture species, with no direct human trials.
  • What dose of Lactobacillus amylovorus is typically used in studies?
    No effective dose has been reported in any of the reviewed studies. The research syntheses indicate that dosing information was not provided across any of the 11 studies covering all three outcomes, so no dose range can be recommended based on current evidence.
  • Who benefits most from Lactobacillus amylovorus?
    Based on available research, benefits have only been observed in animal populations—specifically weaning pigs, newborn piglets, lambs, and fish (Asian seabass fingerlings). No human studies exist, so it is unknown whether any human group would benefit.
  • Are there caveats or limitations in the research on Lactobacillus amylovorus?
    Yes. The evidence base is small (3-4 studies per outcome), all studies are in animals or in vitro except one human meta-analysis for inflammation, publication bias is likely, and many studies did not report doses or statistical significance. Additionally, two of three intestinal barrier studies used co-interventions, making the specific effect uncertain.
  • Does Lactobacillus amylovorus help with inflammation?
    Four studies report beneficial effects on inflammation, but only one is a human meta-analysis of 25 RCTs showing a small reduction in C-reactive protein (-0.99 mg/L). The other three are preclinical and may not translate to humans. The evidence strength is low.
  • Does Lactobacillus amylovorus improve intestinal barrier function?
    Three animal studies (piglets, sows, lambs) report moderate beneficial effects on intestinal barrier function, with 2 of 3 reaching statistical significance. However, two of those studies also used other interventions (Bacillus subtilis, epigallocatechin), and no human data are available, so the specific effect is uncertain.

Most-studied combinations with Lactobacillus amylovorus

most supplement research is combination research
Also studied with:Lactobacillus acidophilus (2)
Back to top